23:58 , Jun 5, 2019 |  BC Extra  |  Company News

Management tracks: Settleman to lead Pfizer cancer R&D; plus Roivant, LabCorp and more

Pfizer Inc. (NYSE:PFE) hired Jeff Settleman as SVP and group head of oncology R&D, effective July 1. He was head of oncology research at Calico Life Sciences LLC (South San Francisco, Calif.) and prior to...
22:34 , Apr 22, 2019 |  BC Extra  |  Company News

Management tracks: MeiraGTx, Retrophin, Aduro

MeiraGTx Holdings plc (NASDAQ:MGTX) said Katherine Breedis stepped down as CFO on April 16, a little over six months after she joined the gene therapy company. MeiraGTx said COO Richard Giroux will take on the...
16:56 , Apr 19, 2019 |  BC Week In Review  |  Company News

Castle Creek gets U.S. rights to market Fibrocell's skin disease cell therapy

Castle Creek will pay $7.5 million up front for an exclusive license to commercialize Fibrocell's FCX-007 in the U.S. FCX-007 is a gene-modified autologous fibroblast that carries collagen type VII (COL7A1) to treat recessive dystrophic...
23:40 , Apr 8, 2019 |  BC Extra  |  Company News

Management tracks: WuXi AppTec, Kymab, Acceleron

WuXi AppTec Co. Ltd. (Shanghai:603259; HKSE:2359) hired Frederick Hausheer as CMO. He was CEO of Alpha Omega Oncology Services (San Antonio, Texas) and an associate partner at Alacrita Consulting (Waltham, Mass.). Antibody company Kymab Group...
21:18 , Oct 26, 2018 |  BC Week In Review  |  Clinical News

Castle Creek discontinues Phase II of epidermolysis bullosa compound

Castle Creek Pharmaceuticals LLC (Parsippany, N.J.) discontinued the Phase II DELIVERS trial evaluating topical 1% diacerein (AC-203, CCP-020) to treat epidermolysis bullosa simplex (EBS). According to ClinicalTrials.gov, an IDMC said the trial will not meet...
22:42 , Oct 30, 2017 |  BC Extra  |  Company News

Management Tracks: Biohaven, Selecta

Neurology company Biohaven Pharmaceutical Holding Co. Ltd. (NYSE:BHVN) hired Clifford Bechtold as COO. He was development team leader for genetically defined diseases at Bristol-Myers Squibb Co. (NYSE:BMY). Immunology company Selecta Biosciences Inc. (NASDAQ:SELB) hired John...
19:28 , Jul 14, 2017 |  BC Week In Review  |  Clinical News

Castle Creek begins Phase II/III of topical diacerein to treat epidermolysis bullosa simplex

Castle Creek Pharmaceuticals LLC (Parsippany, N.J.) began the Phase II/III DELIVERS trial to evaluate topical 1% diacerein (AC-203, CCP-020) in about 80 patients ages ≥4 with epidermolysis bullosa simplex. The double-blind, international trial will test...
00:30 , Nov 5, 2016 |  BC Extra  |  Company News

Management tracks

Gene editing company Casebia Therapeutics (Cambridge, Mass.), a JV formed by Bayer AG (Xetra:BAYN) and CRISPR Therapeutics AG (NASDAQ:CRSP), named James Burns president and CEO. He was head of the North American R&D hub at...
07:00 , Oct 10, 2016 |  BC Week In Review  |  Financial News

Castle Creek Pharmaceuticals completes venture financing

Castle Creek Pharmaceuticals LLC , Bedminster, N.J.   Business: Dermatology   Date completed: 2016-09-29   Type: Venture financing   Raised: $48 million   Investor: Fidelity  ...
07:00 , Oct 3, 2016 |  BC Extra  |  Financial News

Rare disease play Castle Creek raises $48M

Specialty dermatology and ear, nose and throat company Castle Creek Pharmaceuticals LLC (Bedminster, N.J.) raised $48 million in a series A round from Fidelity. This quarter, the company expects to begin a pivotal Phase II/III...